IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1963
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.9B
Emily M. Leproust
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$TWST Twist Bioscience Corp | 50 | 49 | 44 | 60 | - | - | -17.8% | -12.7% | 50.8% | -36.7% | -21.5% | 27.3% | 0.0% | 40.0x | $1.9B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Twist Bioscience Corp (TWST) receives a "Hold" rating with a composite score of 50.3/100. It ranks #1963 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for TWST.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 49 | 42 | +7ALPHA |
| MOMENTUM | 60 | 60 | 0NEUTRAL |
| VALUATION | 44 | 33 | +11ALPHA |
| INVESTMENT | 40 | 75 | -35DRAG |
| STABILITY | 39 | 28 | +11ALPHA |
| SHORT INT | 31 | 21 | +10ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -17.8% (sector -1.9%)
GM 51% vs sector 44%, OM -37% vs sector 3%
Capital turnover N/A, R&D intensity 16.5%
Rev growth 27%, 8yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Twist Bioscience Corp (TWST) as a Hold with a composite score of 50.3/100 at a current price of $48.47. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Twist Bioscience Corp holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 50.3/100 places it at rank #1963 in our full universe.
The near-term outlook is constructive, with revenue growing at 27% and momentum in the 60th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
High
Poor
Fair Value
Gross margins of 51% signal strong pricing power.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
Twist Bioscience Corp represents a hold based on multi-factor quantitative performance.
Our model assigns Twist Bioscience Corp a Hold rating, with a composite score of 50.3/100 and 3 out of 5 stars. Ranked #1963 of 7,333 stocks, TWST presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 49/100, TWST shows adequate but unremarkable business quality. The company reports a return on equity of -17.8% (sector avg: -1.9%), gross margins of 50.8% (sector avg: 44.1%), net margins of -21.5% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
With a value score of 44/100, TWST appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 6.53x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
With an investment score of 40/100, TWST exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 27.3% vs. a sector average of 6.7% and a return on assets of -12.7% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
TWST demonstrates moderate momentum with a score of 60/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 27.3% year-over-year, while a beta of 1.65 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
TWST's stability score of 39/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.65 and a debt-to-equity ratio of 40.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Twist Bioscience Corp's short interest score of 31/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.65), elevated leverage (D/E: 40.00x), small-cap liquidity risk. At $1.9B (small-cap), TWST carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Twist Bioscience Corp is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1963 of 7,333 overall (73rd percentile). Key comparisons include ROE of -17.8% trailing the -1.9% sector median and operating margins of -36.7% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While TWST currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Short Int. (31) is the limiting factor — improvement here would lift the composite score most.
ROE 835% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 15% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 1563% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Twist Bioscience (NasdaqGS:TWST) has entered a co-exclusive licensing agreement for Invenra's bispecific antibody platform. The deal includes an equity stake in Invenra and a seat on Invenra's board of directors. The agreement expands Twist's antibody discovery services into bispecific antibody discovery. For you as an investor, this move extends Twist Bioscience's role beyond DNA synthesis and antibody discovery into a broader bispecific antibody offering, an area that has drawn attention...
Twist Bioscience (NasdaqGS:TWST) agreed to license Invenra’s B-Body bispecific antibody platform on a co exclusive basis, while also taking an equity stake and a board seat in Invenra. The company also introduced new advanced library preparation kits aimed at next generation sequencing and clinical research customers. For you as an investor, these moves sit at the intersection of antibody discovery and genomics tools, which is where Twist Bioscience has been building its business. The tie...
SOUTH SAN FRANCISCO, Calif., February 17, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform ("B-Body platform"),
Twist Bioscience reported strong Q3 results with 18% revenue growth, achieving profitability through a one-time gain and improved operational efficiency. The company saw growth in Next Generation Sequencing and strategic product launches while managing slower Synthetic Biology segment performance.
ARK Invest's 2025 performance data shows the ARK Innovation ETF delivered a 35.5% return, significantly outperforming the S&P 500's 16.6% gain. Top performers included Robinhood Markets (+204%), Palantir Technologies (+135%), and AMD (+77%), while notable losers were The Trade Desk (-68%), Recursion Pharmaceuticals (-40%), and Twist Bioscience (-32%). ARK maintains conviction in underperforming positions based on long-term platform objectives.